CJC-1295: What the Research Shows

CJC-1295 is a synthetic 30-amino-acid peptide analog of growth hormone-releasing hormone (GHRH, also called somatoliberin). GHRH is the naturally occurring hypothalamic hormone that stimulates the pituitary gland to release growth hormone. CJC-1295 was developed to provide a longer-acting alternative to native GHRH, which has a very short half-life (minutes) in the bloodstream.

There are two distinct forms of CJC-1295, and the distinction matters:

CJC-1295 DAC (Drug Affinity Complex). This version includes a proprietary maleimido modification that binds covalently to serum albumin after injection, extending the half-life to approximately 6-8 days. This allows weekly or twice-weekly dosing and produces sustained GH and IGF-1 elevation. It was developed by ConjuChem Biotechnologies and is the version used in the published clinical studies.

CJC-1295 without DAC (Modified GRF 1-29). This version lacks the albumin-binding modification and has a much shorter half-life (~30 minutes). It produces a more acute, pulsatile GH release pattern and requires more frequent administration (typically 1-3 times daily). In the peptide community, this form is often preferred because it more closely mimics natural GHRH signaling.

Both forms share the same core amino acid modifications to the GHRH(1-29) sequence that resist enzymatic degradation (DPP-IV) — specifically substitutions at positions 2, 8, 15, and 27.

CJC-1295 works by binding to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and secretion of growth hormone through the same receptor pathway used by endogenous GHRH.

GHRH receptor activation. CJC-1295 activates the GHRH receptor, triggering intracellular cAMP signaling that leads to GH gene transcription, GH synthesis, and GH release. This is the same pathway used by the body's own GHRH but with longer duration due to the peptide's resistance to enzymatic degradation.

Preserved pulsatility. A key finding from the clinical studies is that even during continuous stimulation by CJC-1295 DAC, the pituitary maintains pulsatile GH secretion rather than constant elevated output. The enhanced trough GH levels (between pulses) appear to be the main driver of increased IGF-1 production (Ionescu & Bhatt, 2006; PMID: 17018654).

Synergy with ghrelin pathway. GHRH and ghrelin act through different receptors on the same pituitary somatotroph cells. GHRH activates the GHRHR (Gs-coupled, increases cAMP) while ghrelin activates the GHSR (Gq-coupled, increases intracellular calcium). These pathways converge synergistically — simultaneous activation produces GH release greater than either signal alone. This is the rationale for combining CJC-1295 with ipamorelin or other ghrelin mimetics.

Negative feedback preserved. Unlike exogenous GH injection, CJC-1295 works through the body's own regulatory system. Somatostatin (the GH-inhibiting hormone) still exerts negative feedback control, which is why GH pulsatility is maintained rather than producing continuous supraphysiological levels.

CJC-1295 has limited but notable human clinical data, primarily from trials conducted by ConjuChem Biotechnologies.

Ascending dose study (n=33). The foundational human study by Teichman et al. (2006; PMID: 16352683) enrolled healthy adults ages 21-61 in two randomized, placebo-controlled, double-blind trials. Single subcutaneous injections of CJC-1295 DAC at doses of 30, 60, or 90 μg/kg produced dose-dependent increases in mean plasma GH concentrations by 2-10 fold for 6 or more days, and IGF-1 increases of 1.5-3 fold lasting 9-11 days. The 60 μg/kg dose was identified as the optimal balance of efficacy and tolerability.

Multiple dose study. Weekly dosing over 2-4 weeks showed cumulative effects — GH and IGF-1 levels increased progressively with each injection. After multiple 60-90 μg/kg doses, 24-hour mean GH levels were sustained at 2-10x baseline throughout the dosing period.

Pulsatility study (n=21). Ionescu and Bhatt (2006; PMID: 17018654) conducted a detailed GH pulsatility analysis showing that CJC-1295 DAC increased both trough and mean GH levels while preserving the normal pulsatile secretion pattern. This finding distinguished CJC-1295 from exogenous GH, which disrupts normal pulsatility.

Serum protein profile changes. Alba et al. (2008; PMID: PMC2787983) showed that CJC-1295 activation of the GH/IGF-1 axis produced characteristic changes in serum protein profiles, with increases in IGF-1, IGFBP-3, and other GH-dependent proteins confirming the expected biological cascade.

Safety in trials. CJC-1295 was described as safe and relatively well tolerated in the clinical studies, particularly at the 30 and 60 μg/kg doses. The most common adverse events were injection site reactions, transient flushing, and headache. One clinical development program was reportedly paused after an adverse event, though details are limited in published literature.

Key limitation. All published human data comes from short-term pharmacokinetic and pharmacodynamic studies. No clinical trials have evaluated CJC-1295 for specific clinical endpoints like body composition, physical function, or disease outcomes. The compound was never advanced to Phase 3 trials.

The distinction between CJC-1295 DAC and CJC-1295 without DAC is one of the most misunderstood topics in the peptide space.

CJC-1295 DAC. The Drug Affinity Complex allows the peptide to bind covalently to albumin in the blood, extending the half-life from minutes to approximately 6-8 days. This produces sustained, continuous GHRH receptor stimulation, elevated baseline GH levels, and steady IGF-1 elevation. It is the form used in all published clinical studies. Dosing is typically weekly.

CJC-1295 without DAC (Modified GRF 1-29). Without the albumin-binding moiety, this form has a half-life of approximately 30 minutes. It produces an acute GH pulse that more closely mimics the natural GHRH signal — a brief burst of GH followed by return to baseline. This requires multiple daily injections (typically 1-3 times daily, often before bed or fasting).

Which is "better"? This depends on the goal. The DAC version produces higher sustained IGF-1 levels and is more convenient (weekly dosing). The no-DAC version produces more physiological GH pulsatility and may carry less risk of sustained IGF-1 elevation. Many practitioners in the peptide community prefer the no-DAC form, believing that preserving sharp GH pulses (rather than blunted continuous elevation) better mimics youthful GH physiology.

Important caveat. All published human safety and efficacy data is for CJC-1295 DAC. The no-DAC form (Modified GRF 1-29) has essentially no published human clinical trial data of its own — its use is based on pharmacological reasoning extrapolated from the GHRH peptide literature and the DAC version's clinical data.

The combination of CJC-1295 (typically without DAC) and ipamorelin is one of the most popular growth hormone secretagogue stacks. The rationale is pharmacologically sound even though clinical data on the specific combination is limited.

Complementary pathways. CJC-1295 activates the GHRH receptor (Gs-coupled, cAMP pathway) while ipamorelin activates the ghrelin receptor/GHSR (Gq-coupled, calcium pathway). When both receptors are activated simultaneously on pituitary somatotrophs, the intracellular signals converge to produce GH release greater than either agent alone. This synergy between GHRH and ghrelin pathways is well-established in basic endocrinology.

Selectivity of ipamorelin. Ipamorelin was chosen as the preferred GHSR agonist pairing because of its selectivity — it stimulates GH release without significantly affecting cortisol, prolactin, or appetite (unlike GHRP-6 or MK-677). This clean profile complements CJC-1295's equally clean GHRH-pathway stimulation.

Clinical evidence for the combination. No published clinical trial has specifically studied the CJC-1295 + ipamorelin combination. The rationale is based on: (1) the well-established GHRH-ghrelin synergy in GH release, (2) the individual clinical and preclinical data for each peptide, and (3) anecdotal reports from clinical practitioners. This is an important limitation — the combination's safety and efficacy profile has not been formally evaluated in humans.

CJC-1295 has a limited but reassuring safety profile from the published clinical studies, though significant gaps exist.

Clinical trial safety. In the Teichman et al. studies, CJC-1295 DAC was described as safe and well tolerated at 30 and 60 μg/kg doses. Common side effects included injection site reactions (redness, swelling), transient flushing or warmth, headache, and diarrhea. These were generally mild and self-limiting.

Dose-dependent side effects. At the highest tested dose (90 μg/kg), side effects were more frequent and included more pronounced flushing and injection site reactions. The 60 μg/kg dose was considered the optimal efficacy-tolerability balance.

Theoretical concerns. As with any agent that chronically elevates GH and IGF-1 levels, theoretical concerns include insulin resistance, fluid retention, joint pain, and the epidemiological association between elevated IGF-1 and certain cancers. None of these were observed in the short-term clinical trials, but long-term safety data does not exist.

Regulatory status. CJC-1295 was placed on the FDA Category 2 list, prohibiting its production by compounding pharmacies for human use. It is WADA-prohibited under the growth hormone secretagogue category. It has never been FDA-approved for any human indication.

No-DAC safety data gap. The Modified GRF 1-29 (no-DAC) form that is widely used in the peptide community has essentially no published human safety data of its own. Users are extrapolating from the DAC version's clinical data and general GHRH peptide pharmacology.